Cargando…
Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome
Labrune syndrome (LS) is caused by SNORD118 gene mutations with a particular neuroimaging of white matter disease, intracranial calcification, and cysts. There was no effective treatment until now. An 18-year-old man with infancy-onset LS was first treated with vascular endothelial growth factor (VE...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552879/ https://www.ncbi.nlm.nih.gov/pubmed/36237624 http://dx.doi.org/10.3389/fneur.2022.968403 |
_version_ | 1784806346207526912 |
---|---|
author | Wang, Meiping Lu, Jinmei Wang, Xiaoxi Ba, Xiaoqun Wu, Dengchang Zhang, Jianfang Zhou, Jiajia Wang, Kang |
author_facet | Wang, Meiping Lu, Jinmei Wang, Xiaoxi Ba, Xiaoqun Wu, Dengchang Zhang, Jianfang Zhou, Jiajia Wang, Kang |
author_sort | Wang, Meiping |
collection | PubMed |
description | Labrune syndrome (LS) is caused by SNORD118 gene mutations with a particular neuroimaging of white matter disease, intracranial calcification, and cysts. There was no effective treatment until now. An 18-year-old man with infancy-onset LS was first treated with vascular endothelial growth factor (VEGF) inhibitor Bevacizumab for 1 year, resulting in significant clinical and radiological improvements. We adopted a similar regimen in a patient with late-onset LS and demonstrated moderate cognitive improvements but without changes in imaging. As such, Bevacizumab could potentially be clinically effective in adult-onset LS with great safety. |
format | Online Article Text |
id | pubmed-9552879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95528792022-10-12 Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome Wang, Meiping Lu, Jinmei Wang, Xiaoxi Ba, Xiaoqun Wu, Dengchang Zhang, Jianfang Zhou, Jiajia Wang, Kang Front Neurol Neurology Labrune syndrome (LS) is caused by SNORD118 gene mutations with a particular neuroimaging of white matter disease, intracranial calcification, and cysts. There was no effective treatment until now. An 18-year-old man with infancy-onset LS was first treated with vascular endothelial growth factor (VEGF) inhibitor Bevacizumab for 1 year, resulting in significant clinical and radiological improvements. We adopted a similar regimen in a patient with late-onset LS and demonstrated moderate cognitive improvements but without changes in imaging. As such, Bevacizumab could potentially be clinically effective in adult-onset LS with great safety. Frontiers Media S.A. 2022-09-27 /pmc/articles/PMC9552879/ /pubmed/36237624 http://dx.doi.org/10.3389/fneur.2022.968403 Text en Copyright © 2022 Wang, Lu, Wang, Ba, Wu, Zhang, Zhou and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Wang, Meiping Lu, Jinmei Wang, Xiaoxi Ba, Xiaoqun Wu, Dengchang Zhang, Jianfang Zhou, Jiajia Wang, Kang Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title | Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title_full | Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title_fullStr | Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title_full_unstemmed | Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title_short | Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome |
title_sort | case report: moderate therapeutic response to bevacizumab in late-onset labrune syndrome |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552879/ https://www.ncbi.nlm.nih.gov/pubmed/36237624 http://dx.doi.org/10.3389/fneur.2022.968403 |
work_keys_str_mv | AT wangmeiping casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT lujinmei casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT wangxiaoxi casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT baxiaoqun casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT wudengchang casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT zhangjianfang casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT zhoujiajia casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome AT wangkang casereportmoderatetherapeuticresponsetobevacizumabinlateonsetlabrunesyndrome |